JP2006512361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512361A5 JP2006512361A5 JP2004561920A JP2004561920A JP2006512361A5 JP 2006512361 A5 JP2006512361 A5 JP 2006512361A5 JP 2004561920 A JP2004561920 A JP 2004561920A JP 2004561920 A JP2004561920 A JP 2004561920A JP 2006512361 A5 JP2006512361 A5 JP 2006512361A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- transfer protein
- cholesteryl ester
- protein inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 9
- 239000002156 adsorbate Substances 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 3
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 2
- CMSGWTNRGKRWGS-NQIIRXRSSA-N Torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims 2
- 230000002378 acidificating Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 230000001264 neutralization Effects 0.000 claims 2
- VHSPKQAESIGBIC-HSZRJFAPSA-N (2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(Cl)C(CC)=CC(OC=2C=C(C=CC=2)N(C[C@@H](O)C(F)(F)F)CC=2C=C(OC(F)(F)C(F)F)C=CC=2)=C1 VHSPKQAESIGBIC-HSZRJFAPSA-N 0.000 claims 1
- VDSBXXDKCUBMQC-VUOWKATKSA-N (4S,6R)-6-[(E)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@@H]2OC(=O)C[C@@H](O)C2)=C1 VDSBXXDKCUBMQC-VUOWKATKSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 229950003040 Dalvastatin Drugs 0.000 claims 1
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 Mevastatin Drugs 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229950004514 Torcetrapib Drugs 0.000 claims 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1S,4aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2S)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 150000002596 lactones Chemical group 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- -1 pitivastatin Chemical compound 0.000 claims 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 claims 1
- TUPKOWFPVAXQFP-OFNKIYASSA-N propan-2-yl (2R,4S)-4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate Chemical group CC(=O)N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 TUPKOWFPVAXQFP-OFNKIYASSA-N 0.000 claims 1
- 230000035489 relative bioavailability Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Claims (14)
- (a)コレステリルエステル転移タンパク質阻害剤および基体からなる固体の非晶質吸着物;および
(b)HMG−CoAレダクターゼ阻害剤
からなる組成物。 - 組成物が濃度増大性ポリマーをさらに含む、請求項1記載の組成物。
- 固体の非晶質吸着物が濃度増大性ポリマーをさらに含む、請求項2記載の組成物。
- 濃度増大性ポリマーが中性非セルロースポリマー、イオン化可能な非セルロースポリマー、中性セルロースポリマー、イオン化可能なセルロースポリマー、酸性ポリマー、中和された酸性ポリマーおよびそのブレンドからなる群より選択される、請求項2または3記載の組成物。
- コレステリルエステル転移タンパク質阻害剤が式I、式II、式III、式IV、式V、式VI
、式VII、式VIII、式IX、式X、式XI、式XII、式XIII、式XIV、式XV、式XVI、式XVII、式XVIII、および式XIXの化合物からなる群より選択される、請求項1〜3のいずれか1項記載の組成物。 - コレステリルエステル転移タンパク質阻害剤が[2R,4S]−4−[アセチル−(3,5−ビス−トリフルオロメチル−ベンジル)−アミノ]−2−エチル−6−トリフルオロメチル−3,4−ジヒドロ−2H−キノリン−1−カルボン酸イソプロピルエステル、[2R,4S]−4−[(3,5−ビス−トリフルオロメチル−ベンジル)−メトキシカルボニル−アミノ]−2−エチル−6−トリフルオロメチル−3,4−ジヒドロ−2H−キノリン−1−カルボン酸エチルエステル、(2R)−3−[[3−(4−クロロ−3−エチルフェノキシ)フェニル][[3−(1,1,2,2−テトラフルオロエトキシ)フェニル]メチル]アミノ]−1,1,1−トリフルオロ−2−プロパノールおよび[2R,4S]4−[(3,5−ビス−トリフルオロメチル−ベンジル)−メトキシカルボニル−アミノ]−2−エチル−6−トリフルオロメチル−3,4−ジヒドロ−2H−キノリン−1−カ
ルボン酸イソプロピルエステルからなる群より選択される、請求項1〜3のいずれか1項記載の組成物。 - HMG−CoAレダクターゼ阻害剤がフルバスタチン、ロバスタチン、プラバスタチン、アトルバスタチン、シンバスタチン、セリバスタチン、リバスタチン、メバスタチン、ベロスタチン、コムパクチン、ダルバスタチン、フルインドスタチン、ロスバスタチン、ピチバスタチン、ジヒドロコンパクチンおよびその製薬上許容される形態からなる群より選択される、請求項1〜3のいずれか1項記載の組成物。
- HMG−CoAレダクターゼ阻害剤がアトルバスタチン、アトルバスタチンの環化されたラクトン形態、このような化合物の2−ヒドロキシ、3−ヒドロキシまたは4−ヒドロキシ誘導体、およびその製薬上許容される形態からなる群より選択される、請求項1〜3のいずれか1項記載の組成物。
- トルセトラピブならびに、アトルバスタチンおよびその製薬上許容される形態からなる群より選択されるHMG−CoAレダクターゼ阻害剤を含む、請求項1〜3のいずれか1項記載の組成物。
- 組成物が、インビボまたはインビトロの使用のための水性環境に投与後、以下
(a)本質的にコレステリルエステル転移タンパク質阻害剤だけからなる対照組成物と比較して、少なくとも1.25倍の、使用環境におけるコレステリルエステル転移タンパク質阻害剤の最大濃度の改善;
(b)本質的にコレステリルエステル転移タンパク質阻害剤だけからなる対照組成物の少なくとも1.25倍である、使用環境への導入の時間から使用環境への導入後約270分の間の少なくとも90分の任意の期間の、使用環境中のコレステリルエステル転移タンパク質阻害剤の濃度対時間曲線下面積;
(c)本質的にコレステリルエステル転移タンパク質阻害剤だけからなる対照組成物と比較して少なくとも1.25倍のコレステリルエステル転移タンパク質阻害剤の相対的バイオアベイラビリティーの改善;および
(d)本質的にコレステリルエステル転移タンパク質阻害剤だけからなる対照組成物と比較して少なくとも1.25倍の血中コレステリルエステル転移タンパク質阻害剤の最大濃度の改善、
の少なくとも1つを与える、請求項1〜3のいずれか1項記載の組成物。 - 固体の非晶質吸着物が溶解促進剤をさらに含む、請求項1〜3のいずれか1項記載の組成物。
- 固体の非晶質吸着物が少なくとも0.005分-1の溶解速度定数を有する、請求項1〜3のいずれか1項記載の組成物。
- 基体が約200m2/gまたはそれ以上の表面積を有する、請求項1〜3のいずれか1
項記載の組成物。 - 請求項1〜13のいずれか1項記載の組成物を含む、カプセル剤、丸剤および錠剤からなる群より選択される剤形。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43532802P | 2002-12-20 | 2002-12-20 | |
PCT/IB2003/006170 WO2004056395A1 (en) | 2002-12-20 | 2003-12-18 | Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006512361A JP2006512361A (ja) | 2006-04-13 |
JP2006512361A5 true JP2006512361A5 (ja) | 2007-02-08 |
Family
ID=32682218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004561920A Pending JP2006512361A (ja) | 2002-12-20 | 2003-12-18 | コレステリルエステル転移タンパク質阻害剤およびHMG−CoAレダクターゼ阻害剤の組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040132771A1 (ja) |
EP (1) | EP1578448A1 (ja) |
JP (1) | JP2006512361A (ja) |
AU (2) | AU2003285677A1 (ja) |
BR (1) | BR0317520A (ja) |
CA (1) | CA2510458A1 (ja) |
MX (1) | MXPA05006167A (ja) |
WO (2) | WO2004056396A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040015746A (ko) * | 2001-06-21 | 2004-02-19 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제 |
BR0317593A (pt) * | 2002-12-20 | 2005-11-22 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase |
GEP20084406B (en) | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
US20080145427A1 (en) * | 2005-02-03 | 2008-06-19 | Alfred Berchielli | Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
EP1893178A1 (en) * | 2005-05-31 | 2008-03-05 | Pfizer Products Incorporated | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
US8859011B2 (en) | 2006-05-12 | 2014-10-14 | Particle Dynamics International, Llc | Calcium compositions |
US8099298B2 (en) * | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
CA2716671A1 (en) * | 2008-02-27 | 2009-09-03 | Thommen Medical Ag | Implant and method for the manufacture thereof |
CN102083467B (zh) * | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
US20110098315A1 (en) * | 2008-06-27 | 2011-04-28 | Farhad Sayyad Farshi | Pharmaceutical compositions of rosuvastatin calcium |
WO2010092925A1 (ja) * | 2009-02-12 | 2010-08-19 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
WO2014121133A2 (en) | 2013-02-03 | 2014-08-07 | Genelex Corporation | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US35125A (en) * | 1862-04-29 | Improvement in spring-balances | ||
JPS5612114B2 (ja) * | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4319039A (en) * | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
US4294926A (en) * | 1979-06-15 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
JPS5889191A (ja) * | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | 3−ヒドロキシ−ml−236b誘導体の製造法 |
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4911165A (en) * | 1983-01-12 | 1990-03-27 | Ethicon, Inc. | Pliabilized polypropylene surgical filaments |
US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US5569469A (en) * | 1984-10-16 | 1996-10-29 | Vectorpharma International, S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
US5225192A (en) * | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5110940A (en) * | 1987-02-25 | 1992-05-05 | Bristol-Myers Company | Antihypercholesterolemic tetrazole compounds |
US4820850A (en) * | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
US5049696A (en) * | 1988-04-11 | 1991-09-17 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US4866058A (en) * | 1988-07-27 | 1989-09-12 | Izydore Robert A | Method for control of hyperlipidemia |
IT1226726B (it) * | 1988-07-29 | 1991-02-05 | Zambon Spa | Composti attivi come inibitori della biosintesi del colesterolo. |
US5196440A (en) * | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
US5011947A (en) * | 1988-08-25 | 1991-04-30 | Bristol-Myers | Antihypercholesterolemic alkylene compounds |
US5290946A (en) * | 1988-10-13 | 1994-03-01 | Sandoz Ltd. | Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes |
US5118853A (en) * | 1988-10-13 | 1992-06-02 | Sandoz Ltd. | Processes for the synthesis of 3-disubstituted aminoacroleins |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5099035A (en) * | 1989-02-27 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
US5166364A (en) * | 1989-02-27 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
US5189164A (en) * | 1989-05-22 | 1993-02-23 | Sandoz Ltd. | Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof |
US5010105A (en) * | 1989-06-09 | 1991-04-23 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4949437A (en) * | 1989-07-11 | 1990-08-21 | Anderson Travis B | Shoelace knot retaining apparatus |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5106992A (en) * | 1989-07-28 | 1992-04-21 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
US4970221A (en) * | 1989-07-28 | 1990-11-13 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
US5189180A (en) * | 1989-09-28 | 1993-02-23 | E. R. Squibb & Sons, Inc. | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates |
US5025017A (en) * | 1989-09-28 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates |
US5217992A (en) * | 1989-10-04 | 1993-06-08 | Bristol-Myers Squibb Company | Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders |
IT1237793B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5157134A (en) * | 1992-03-12 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Dihydroxyheptanoic acids containing an oxabicycloheptane nucleus useful as antihypercholesterolemic agents |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
US6207671B1 (en) * | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
JPH11131049A (ja) * | 1997-10-28 | 1999-05-18 | Japan Science & Technology Corp | シリカ有機物複合体とその製造方法 |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
AU2001270937A1 (en) * | 2000-08-15 | 2002-02-25 | Pfizer Products Inc. | Therapeutic combination |
JP4547148B2 (ja) * | 2001-06-22 | 2010-09-22 | ベンド・リサーチ・インコーポレーテッド | 非晶質薬剤の吸着物の医薬組成物 |
JP2005509001A (ja) * | 2001-10-29 | 2005-04-07 | セリクス, インコーポレイテッド | 投薬形態の三次元懸濁液プリンティング |
AU2003260239A1 (en) * | 2002-06-26 | 2004-01-19 | Tuo Jin | Solid dosage forms for rapid dissolution of poorly soluble drugs |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
-
2003
- 2003-10-06 US US10/678,145 patent/US20040132771A1/en not_active Abandoned
- 2003-12-18 WO PCT/IB2003/006240 patent/WO2004056396A1/en not_active Application Discontinuation
- 2003-12-18 WO PCT/IB2003/006170 patent/WO2004056395A1/en active Application Filing
- 2003-12-18 AU AU2003285677A patent/AU2003285677A1/en not_active Abandoned
- 2003-12-18 JP JP2004561920A patent/JP2006512361A/ja active Pending
- 2003-12-18 MX MXPA05006167A patent/MXPA05006167A/es not_active Application Discontinuation
- 2003-12-18 AU AU2003285703A patent/AU2003285703A1/en not_active Abandoned
- 2003-12-18 CA CA002510458A patent/CA2510458A1/en not_active Abandoned
- 2003-12-18 BR BR0317520-0A patent/BR0317520A/pt not_active IP Right Cessation
- 2003-12-18 EP EP03778668A patent/EP1578448A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006512361A5 (ja) | ||
RU2005119176A (ru) | Лекарственные формы, содержащие ингибитор сетр и ингибитор hmg-coa-редуктазы | |
AU2012231944B2 (en) | Oral complex composition comprising omega-3 fatty acid ester and HMG-CoA reductase inhibitor | |
ATA13602000A (de) | Stabilisierte pharmazeutische präparation eines hmg-coa reduktase hemmers | |
JP2008526861A5 (ja) | ||
JP2010047616A5 (ja) | ||
RU2011117059A (ru) | Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений | |
JP2022116083A5 (ja) | ||
JP2007277267A5 (ja) | ||
ATE353214T1 (de) | Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung | |
IL171962A (en) | Use of a DP receptor antagonist and nicotinic acid in the preparation of a drug for the treatment of dyslipidemia and related diseases in the absence of flushing, and medical vaccines containing them | |
JP2007523049A5 (ja) | ||
PE20001054A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas | |
SK1402004A3 (sk) | Spôsob prípravy vápenatých solí statinov | |
JP2005200419A5 (ja) | ||
JP2007530528A5 (ja) | ||
HUP0104240A2 (hu) | Eljárás ateroszklerozis kezelésére egy aP2 inhibítor vagy kombinációja alkalmazásával | |
WO2008058897A3 (en) | Diphyllin and other lignans as a medicament for v-atpase mediated disease | |
NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
CA2660151C (en) | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | |
CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
DE602006019710D1 (de) | Magnesiumsalze von hmg-coa-reduktase-hemmern | |
JP2007512347A5 (ja) | ||
TW200744583A (en) | Statin stabilizing dosage formulations | |
WO2004071402A3 (en) | STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR |